KORU Medical Systems (NASDAQ:KRMD) (NASDAQ: KRMD) specializes in the development and commercialization of minimally invasive medical devices designed to treat vascular and circulatory disorders. The company's core technology, endoscopic lumbar sympathectomy (ELS), targets sympathetic nerve pathways to improve blood flow to the lower extremities. KORU Medical’s flagship offering, the Nevascu™ System, combines endoscopic visualization with computer-assisted mapping to perform precise neuro-modulation procedures for patients suffering from chronic peripheral arterial disease (PAD) and Raynaud’s phenomenon.
The Nevascu System integrates proprietary software, specialized endoscopic tools and advanced imaging components to guide physicians through a one-hour outpatient procedure. By selectively interrupting overactive sympathetic nerves, the system aims to reduce pain, promote vasodilation and enhance wound healing in ischemic tissues. KORU Medical also provides procedural training, clinical support and ongoing data collection to partner physicians, supporting faster adoption and optimal patient outcomes. The company continues to refine its technology platform, exploring potential applications in other neuromodulation therapies.
Founded in the early 2000s and headquartered in Laguna Hills, California, KORU Medical has secured multiple U.S. Food and Drug Administration (FDA) clearances and expanded its sales and training footprint across North America. The company’s go-to-market strategy emphasizes collaboration with vascular surgeons, interventional radiologists and wound care specialists. In addition to its U.S. operations, KORU Medical is evaluating opportunities in Europe and Asia, seeking regulatory approvals and distribution partnerships to broaden access to its ELS technology.
KORU Medical’s leadership team combines executives with extensive experience in medical device innovation, regulatory affairs and commercial operations. The board of directors includes veterans from endoscopy, cardiovascular and surgical markets, ensuring a balanced focus on product development, clinical validation and revenue growth. With a commitment to advancing minimally invasive therapies, KORU Medical Systems continues to conduct clinical research, pursue intellectual property protections and collaborate with key opinion leaders to address unmet needs in vascular health.
